These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 24709902)

  • 61. C-erbB2, p27 and G1/S aberrations in human primary breast cancer.
    Lodén M; Perris F; Nielsen NH; Emdin SO; Landberg G
    Anticancer Res; 2003; 23(3A):2053-61. PubMed ID: 12894578
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Upregulation of neutrophil gelatinase-associated lipocalin by ErbB2 through nuclear factor-kappaB activation.
    Li SH; Hawthorne VS; Neal CL; Sanghera S; Xu J; Yang J; Guo H; Steeg PS; Yu D
    Cancer Res; 2009 Dec; 69(24):9163-8. PubMed ID: 19951994
    [TBL] [Abstract][Full Text] [Related]  

  • 63. ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation.
    Kedrin D; Wyckoff J; Boimel PJ; Coniglio SJ; Hynes NE; Arteaga CL; Segall JE
    Clin Cancer Res; 2009 Jun; 15(11):3733-9. PubMed ID: 19458057
    [TBL] [Abstract][Full Text] [Related]  

  • 64. TOM1L1 drives membrane delivery of MT1-MMP to promote ERBB2-induced breast cancer cell invasion.
    Chevalier C; Collin G; Descamps S; Touaitahuata H; Simon V; Reymond N; Fernandez L; Milhiet PE; Georget V; Urbach S; Lasorsa L; Orsetti B; Boissière-Michot F; Lopez-Crapez E; Theillet C; Roche S; Benistant C
    Nat Commun; 2016 Feb; 7():10765. PubMed ID: 26899482
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.
    Brantley-Sieders DM; Zhuang G; Hicks D; Fang WB; Hwang Y; Cates JM; Coffman K; Jackson D; Bruckheimer E; Muraoka-Cook RS; Chen J
    J Clin Invest; 2008 Jan; 118(1):64-78. PubMed ID: 18079969
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Expression of ErbB2 enhances radiation-induced NF-kappaB activation.
    Guo G; Wang T; Gao Q; Tamae D; Wong P; Chen T; Chen WC; Shively JE; Wong JY; Li JJ
    Oncogene; 2004 Jan; 23(2):535-45. PubMed ID: 14724581
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer.
    Martinello R; Milani A; Geuna E; Zucchini G; Aversa C; Nuzzo A; Montemurro F
    Expert Opin Investig Drugs; 2016; 25(4):393-403. PubMed ID: 26863927
    [TBL] [Abstract][Full Text] [Related]  

  • 68. ErbB2 and p38γ MAPK mediate alcohol-induced increase in breast cancer stem cells and metastasis.
    Xu M; Ren Z; Wang X; Comer A; Frank JA; Ke ZJ; Huang Y; Zhang Z; Shi X; Wang S; Luo J
    Mol Cancer; 2016 Jul; 15(1):52. PubMed ID: 27416801
    [TBL] [Abstract][Full Text] [Related]  

  • 69. LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression.
    Montañez-Wiscovich ME; Seachrist DD; Landis MD; Visvader J; Andersen B; Keri RA
    Oncogene; 2009 Oct; 28(41):3608-18. PubMed ID: 19648968
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer.
    Zhang J; Li Q; Wu Y; Wang D; Xu L; Zhang Y; Wang S; Wang T; Liu F; Zaky MY; Hou S; Liu S; Zou K; Lei H; Zou L; Zhang Y; Liu H
    Cell Commun Signal; 2019 Feb; 17(1):15. PubMed ID: 30786890
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Shc is required for ErbB2-induced inhibition of apoptosis but is dispensable for cell proliferation and disruption of cell polarity.
    Lucs AV; Muller WJ; Muthuswamy SK
    Oncogene; 2010 Jan; 29(2):174-87. PubMed ID: 19826412
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
    Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
    Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells.
    Zhao M; Howard EW; Parris AB; Guo Z; Zhao Q; Ma Z; Xing Y; Liu B; Edgerton SM; Thor AD; Yang X
    Oncotarget; 2017 Aug; 8(35):58847-58864. PubMed ID: 28938602
    [TBL] [Abstract][Full Text] [Related]  

  • 74. β-Catenin haploinsufficiency promotes mammary tumorigenesis in an ErbB2-positive basal breast cancer model.
    Bui T; Schade B; Cardiff RD; Aina OH; Sanguin-Gendreau V; Muller WJ
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):E707-E716. PubMed ID: 28096336
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
    Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
    Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion.
    Arora P; Cuevas BD; Russo A; Johnson GL; Trejo J
    Oncogene; 2008 Jul; 27(32):4434-45. PubMed ID: 18372913
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Activation of ErbB2 receptor tyrosine kinase supports invasion of endothelial cells by Neisseria meningitidis.
    Hoffmann I; Eugène E; Nassif X; Couraud PO; Bourdoulous S
    J Cell Biol; 2001 Oct; 155(1):133-43. PubMed ID: 11581290
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Inhibition of eIF2alpha dephosphorylation inhibits ErbB2-induced deregulation of mammary acinar morphogenesis.
    Sequeira SJ; Wen HC; Avivar-Valderas A; Farias EF; Aguirre-Ghiso JA
    BMC Cell Biol; 2009 Sep; 10():64. PubMed ID: 19754954
    [TBL] [Abstract][Full Text] [Related]  

  • 79. PTP LAR expression compared to prognostic indices in metastatic and non-metastatic breast cancer.
    Levea CM; Mcgary CT; Symons JR; Mooney RA
    Breast Cancer Res Treat; 2000 Nov; 64(2):221-8. PubMed ID: 11194458
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Modeling ErbB2-p130Cas interaction to design new potential anticancer agents.
    Costamagna A; Rossi Sebastiano M; Natalini D; Simoni M; Valabrega G; Defilippi P; Visentin S; Ermondi G; Turco E; Caron G; Cabodi S
    Sci Rep; 2019 Feb; 9(1):3089. PubMed ID: 30816273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.